Source: NCBI

Citation: Gautret, P., Lagier, J. C., Honoré, S., Hoang, V. T., & Raoult, D. (2021). Clinical efficacy and safety profile of hydroxychloroquine and azithromycin against COVID-19. International journal of antimicrobial agents57(1), 106242.

We agree with colleagues that clinical outcomes are also key elements to consider when assessing the effect of hydroxychloroquine-azythromycin (HCQ-AZ) combination [1]. To this end, we reanalyzed our data on all patients enrolled in our study (n=42) and, in addition to viral clearance over time, we analyzed clinical outcomes, including the need for oxygen therapy, transfer to intensive care unit (ICU), death and length of stay at hospital. Requirement for oxygen therapy, transfer to ICU and death did not significantly differ between groups. Length of stay at hospital and viral persistence were significantly shorter in the treated patients group, compared to the control group. Length of stay was calculated in 38 of 42 patients because two patients died, one was discharged against medical advice and information was missing for one patient (Table 1 ).

Table 1

Characteristics of studied populations.

We agree that the HCQ-AZ combination may potentially lead to drug-drug interactions. We paid a rigorous attention to avoiding this combination in patients with cardiac diseases, abnormal EKG, dyskalemia or the routine use of other interacting medications. The systematic pre-therapy workup included serum electrolyte analysis, and an electrocardiogram with corrected QT measurement (Bazett’s formula).

Close serum electrolyte analysis monitoring was performed in patients with low serum potassium levels at baseline. An electrocardiogram was routinely performed 48 hours after the start of treatment. Treatment with HCQ was discontinued when the corrected QT interval (QTc, Bazett’s formula) was>500ms, and the risk-benefit ratio of HCQ+AZ treatment was estimated by the infectious disease specialist and agreed with the cardiologist to be between 460 and 500ms.

No cases of torsade de pointe or sudden death were observed. Since this paper was published, we have treated a total of 3,119 patients with HCQ-AZ for at least three days. QTc prolongation (>60 ms) was observed in 25 patients (0.67%), resulting in discontinuation of treatment in 12 cases, including three cases with QTc> 500 ms.

No cases of torsade de pointe or sudden death were observed, including in the 9.5% patients over 65 years of age [2]. Finally, we totally agree with colleagues to pay attention to magnesium levels, with supplementation, if needed, to prevent life-threatening arrhythmias.

Related: COVID-19: A realistic approach to community management – HCQ & IVM in concert with vaccination

“I treated Covid not caring about the bans: zero deaths. But they told me to shut up ”▷ Dr. Szumski

Top US medics recommend ‘sequenced multidrug therapy’ including HCQ & Ivermectin, for early high-risk COVID-19 infections

Professor Ananda Prasad at 92 years of age – putting together the pivotal antiviral role of zinc

Share on facebook
Share on twitter
Share on whatsapp
On Trend

Latest Stories

Trouble in Paradise Surrounding the use of Ivermectin

In nations around the world tension mounts between physicians and caregivers seeking to prescribe what they professionally deem as safe doses of ivermectin, as an off-label treatment for COVID-19 and national health authorities, which for the most part have all taken a hostile and oppositional position against the use of the drug.

Read More »

How Ivermectin became a Target for the ‘Fraud Detectives.’

And why is ivermectin being so negatively targeted by Big Tech and Big Media? One could argue conflict of interest plays a major role, given how intertwined they are with Big Pharma and the far-reaching grasp of the BMGF. A cheap and effective early treatment for Covid-19, like ivermectin, can be seen as a significant threat to the financial interests of those involved with Covid vaccines and expensive anti-viral drugs.

Read More »

Canada: Alberta Failing on COVID-19 Vaccines and Treatment

Numerous studies and clinical observation of thousands of patients has indicated that Ivermectin is highly effective in this regard. Even low dose studies that were designed to reach the conclusion that ivermectin was not effective found a signal that indicated that Ivermectin effectively interacted with the COVID virus molecule to prevent or lessen replication of the virus.”

Read More »